The company’s conditionally activated siRNA (CASi) platform integrates RNA nanotechnology with RNA medicinal chemistry to create siRNA pro-drugs that can activate or suppress their own drug activities based on the presence or absence of disease indicating RNA markers in mammalian cells.  This gives CASi based drugs the ability to target specific cells responsible for disease while sparing healthy cells from drug activity. 

Since its founding in Q3 2020, Switch has made significant progress in optimizing its technology for therapeutic applications and has generated highly compelling in vivo validation data demonstrating distribution, potency, and duration of effect that support development for important disease indications. 

The company has recently secured new funding and is gearing up for aggressive growth enabling the next phase of its mission.